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Abstract: History has shown us that wherever antimalarial
drugs are deployed antimalarial drug resistance will follow. A pat-
tern has emerged with the drugs falling to resistance ﬁrst in South
East Asia and subsequently in India, Latin America and Africa. The
decline in chloroquine efﬁcacy led to millions of avoidable deaths
from malaria in sub-Saharan Africa throughout the 1980s and ‘90s.
Artemisinin based combination treatments (ACTs) are the rec-
ommended ﬁrst line treatments for falciparummalaria worldwide.
The unique properties of the artemisinin derivatives, in particular
their ability to reduce peripheral blood parasitaemia rapidly, make
them the most potent antimalarial drug class ever used. They are
partnered with slower acting antimalarial drugs and given over
3 days. Resistance to both the artemisinin derivatives and their
partner drugs (meﬂoquine and piperaquine) has emerged in South
East Asia over the last decade. Now failure rates of the combina-
tions exceed 30% at some locations. Alarmingly, malaria is on the
rise again in western Cambodia where incidence rates had reduced
dramatically over the last decade.
Genetic studies have identiﬁed several mutations in a gene
encoding for aplasmodial kelchproteinassociatedwithartemisinin
resistance. Sampling from several sites throughout Asia has sug-
gested resistance may have emerged multiple times at different
locations. This is unlike chloroquine resistance which is thought
to have emerged only twice and then spread globally. This ﬁnding
has implications for global surveillance andcontainment strategies.
Newer antimalarial drug compounds are in development but are
still several years away from registration. The most practical solu-
tion to contain the threat of antimalarial drug resistance before the
death toll from malaria rises is to intensify our efforts to eliminate
falciparum malaria.
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Declining efﬁcacy of meﬂoquine-artesunate
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Abstract: Background: Meﬂoquine-artesunate treatment of
Plasmodium falciparum malaria in the displaced population on the
Thailand-Myanmar border led to a dramatic decline in transmis-
sion. Efﬁcacyhas fallen substantially in recent years, but the relative
contribution of resistance to the individual drugs is unknown.
Methods: Patients with uncomplicated P. falciparum malaria
receiving supervised meﬂoquine-artesunate treatment were fol-
lowed for 42 days. Molecular testing was undertaken to determine
baseline pfmdr1 copy number, K13 genotype and discriminate
recrudescences.
Findings: 1005 patients were enrolled from 2003-2013, dur-
ing which PCR-adjusted cure rate declined from 100% to 81·1%.
The proportion of isolates with multiple pfmdr1 copies rose from
32·4% to 64·7% while infections with K13 mutation increased from
6·7% to 83·4%. K13 propeller mutations predominated after 2009.
The PCR-adjusted failure rate of infections with both ampliﬁed
pfmdr1andK13propellermutationwas42·2%and theadjustedhaz-
ard ratio was 14·05 (p<0·001). Even without pfmdr1 ampliﬁcation,
K13 propeller mutation was a strong risk factor for recrudescence
(AHR=5·73, p=0·009). The combined population attributable frac-
tion of recrudescence associated with K13 mutation and pfmdr1
ampliﬁcation was 82%.
Interpretation: Pfmdr1 ampliﬁcation and K13 mutation act in
combination to reduce the efﬁcacy of meﬂoquine-artesunate but
the rise in K13 propeller mutations was the decisive factor in the
fall in efﬁcacy to unacceptable levels. These ﬁndings conﬁrm the
strong link between artemisinin resistance and ACT failure, and
demonstrate the relatively short timeframe in which ACT efﬁcacy
can be lost once artemisinin resistance is present.
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